Skip to main content

PharmaCyte Biotech, Inc.

PMCB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001157075

No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by PharmaCyte Biotech, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for PharmaCyte Biotech, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for PharmaCyte Biotech, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Walker Wayne RemellDirector20,625Jul 17, 20262
Abecassis Michael MDirector22,292Jul 17, 20262
Schechter JonathanDirector192,500Jul 17, 20263
Weinstein RobertDirector41,250Jul 17, 20262
Silverman JoshuaCEO and President416,250Jan 7, 20262
Trujillo CarlosChief Financial Officer–Nov 22, 20230
Allen DanielDirector–Dec 30, 20220
Farb Daniel StuartDirector–Dec 30, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 7, 2026 (view filing)Jan 5-72 daysSilverman JoshuaCEO and PresidentPPurchase+100.0K$0.803+$80.3K+31.6%416.3K after3 lots
Jan 7, 2026 (view filing)Jan 5-72 daysSchechter JonathanDirectorPPurchase+60.0K$0.8033+$48.2K+45.3%192.5K after3 lots